Analysis of the Immune Infiltrate in Lesional Skin During Anti-interleukin 23 (IL-23) Therapy in Patients With Moderate-severe Plaque Psoriasis

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques. Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development. Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy. Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• moderate-severe psoriasis PASI\>10

• anti IL 23 biologic therapy for at least 6 months (for the group under treatment)

• during therapy at least one area resistant to treatment or at least one flare of disease (for the group under treatment)

• patients able to express informed consent

Locations
Other Locations
Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia
RECRUITING
Rome
Contact Information
Primary
Ketty Peris, Prof
ketty.peris@policlinicogemelli.it
+390630155284
Time Frame
Start Date: 2024-09-04
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 20
Treatments
Sperimental
Patients affected by moderate-severe psoriasis treated with anti IL-23 therapy for at least 6 months, according to label dose.
No Sperimental
Patients affected by moderate-severe psoriasis that have not been already treated
Related Therapeutic Areas
Sponsors
Leads: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

This content was sourced from clinicaltrials.gov